Cost will be one of the most important factors to determine whether or not a biosimilar pegfilgrastim improves patient access to the treatment, said Leora Horn, MD, clinical director of thoracic oncology at Vanderbilt-Ingraham Cancer Center, assistant vice chancellor for faculty development at Vanderbilt University Medical Center.
Cost will be one of the most important factors to determine whether or not a biosimilar pegfilgrastim improves patient access to the treatment, said Leora Horn, MD, clinical director of thoracic oncology at Vanderbilt-Ingraham Cancer Center, assistant vice chancellor for faculty development at Vanderbilt University Medical Center.
Transcript (slightly modified)
How might a biosimilar pegfilgrastim improve patient access?
So, that’s a good question. I think a lot of that will depend on cost. We can access the drug for patients and with the recent OBI [On-Body Injector] formulation, where patients can get their injection in clinic, on the day of chemo, but it releases 24 hours later when they’re at home; that’s made access a little bit easier that patients don’t have to drive back and forth to the cancer clinic especially when insurance won’t cover the drug.
I think the biggest issue is going to be: is the cost going to be lower? Because as we know for a lot of drugs, you can sort of think of a biosimilar as a generic version of a chemo agent and if the cost of the drug is as high as some of the generic agents we have in the United States, it’s not going to make it any more affordable for our cancer patients.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More